stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Free cash flow
Takeda Pharmaceutical Co.'s free cash flow for fiscal 2026 was $4.2B, down 6.55% from $4.5B in fiscal 2025. Over the twelve months to 30 September 2026 it was $8.0B. Over the past ten years it has ranged from −$488.4M (fiscal 2016) to $8.4B (fiscal 2022); the current reading is higher than 67% of that period. Takeda Pharmaceutical Co. ranks 1st of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2026 | $4.2B | (6.55%) |
| FY2025 | $4.5B | 165.41% |
| FY2024 | $1.7B | (33.89%) |
| FY2023 | $2.5B | (69.50%) |
| FY2022 | $8.4B | 8.29% |
| FY2021 | $7.7B | 80.53% |
| FY2020 | $4.3B | 93.79% |
| FY2019 | $2.2B | (2.96%) |
| FY2018 | $2.3B | 60.44% |
| FY2017 | $1.4B | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $1.6B | 876.76% |
| Jun 2026 | $160.5M | (96.04%) |
| Dec 2025 | $4.0B | 84.24% |
| Sep 2025 | $2.2B | 117.09% |
| 26 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TAK Takeda Pharmaceutical Co. | $8.0B |
| HLN Haleon PLC Sponsored ADR compare | $4.6B |
| VTRS Viatris Inc. compare | $2.4B |
| ZTS Zoetis Inc. compare | $2.3B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.3B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.0B |
| UTHR United Therapeutics Corporation compare | $867.2M |
| ELAN Elanco Animal Health Incorporated compare | $379.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $96.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on TAK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement